References
- Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117:591–594.
- ZYDELIG (idelalisib tablets). Full prescribing information, Gilead Sciences, Inc., Foster City, CA, 2014.
- ZYDELIG (idelalisib tablets). Summary of product characteristics, Gilead Sciences International Ltd, Cambridge, UK, 2014.
- Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261–1274.
- Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol 2003;3:317–330.
- Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272:19236–19241.
- Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603–3612.
- Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22:8580–8591.
- Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88–92.
- Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563–574.
- Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:1008–1018.
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370: 997–1007.
- Data on file. Gilead Sciences, Inc., Foster City, CA, 2014.
- Flinn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-δ,γ inhibitor, in patients with relapsed/refractory iNHL. Blood 2014;124(Suppl. 1): Abstract 802.
- Uno JK, Rao KN, Matsuoka K, et al. Altered macrophage function contributes to colitis in mice defective in the phosphoinositide-3 kinase subunit p110delta. Gastroenterology 2010;139:1642–1653, 1653.e1–6.
- Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918–2926.
- Duran I, Goebell PJ, Papazisis K, et al. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf 2014;13:361–372.
- Byrd JC, Woyach JA, Johnson AJ. Translating PI3K-delta inhibitors to the clinic in chronic lymphocytic leukemia: the story of CAL-101 (GS1101). Am Soc Clin Oncol Educ Book 2012;32:691–694.
- Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078–2088.
- Jin F, Robeson M, Zhou H, et al. Drug interaction profile of idelalisib and its major metabolit, GS-563117. J Clin Oncol 2014; 32(Suppl.): Abstract 2593.
- American Cancer Society. Caring for the patient with cancer at home: a guide for patients and families. 2013. Available from: www.cancer.org/acs/groups/cid/documents/webcontent/002818-pdf.pdf
- National Cancer Institute. Managing chemotherapy side effects: diarrhea. 2012. Available from: www.cancer.gov/cancertopics/coping/chemo-side-effects/diarrhea.pdf
- Entocort® EC (budesonide). Full prescribing information, AstraZeneca LP, Wilmington, DE, 2011.